Erlotinib Completed Phase 1 Trials for Malignant Diseases Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00881166Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors